Moderna Financial Statements From 2010 to 2022

MRNA -  USA Stock  

USD 132.06  5.56  4.04%

Moderna financial statements provide useful quarterly and yearly information to potential Moderna investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Moderna financial statements helps investors assess Moderna's valuation, profitability, and current liquidity needs.
We have found eighty-two available fundamental ratios for Moderna, which can be analyzed and compared to other ratios and to its peers in the industry. Make sure you check all of Moderna last-minute market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
The current year Average Assets is expected to grow to about 20.1 B. The current year Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to grow to about 14.6 B.
  
Refresh
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna main balance sheet or income statement drivers, such as Consolidated Income of 13.2 B, Cost of Revenue of 2.1 B or Earning Before Interest and Taxes EBIT of 14.3 B, as well as many exotic indicators such as Asset Turnover of 1.07, Book Value per Share of 37.87 or Current Ratio of 1.81. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules. It can also supplement various Moderna Technical models. Additionally, see the analysis of Moderna Correlation against competitors.

Moderna Revenues

19.93 Billion

Share

Moderna Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets26.6 B24.7 B5.6 B
Increasing
Slightly volatile
Cash and Equivalents7.4 B6.8 B1.4 B
Increasing
Slightly volatile
Investments11.6 B10.7 B2.8 B
Increasing
Slightly volatile
Investments Current4.2 B3.9 B1.5 B
Increasing
Slightly volatile
Investments Non Current7.4 B6.9 B1.3 B
Increasing
Slightly volatile
Deferred Revenue7.4 B6.9 B1.7 B
Increasing
Slightly volatile
Property Plant and Equipment Net1.5 B1.4 B343.8 M
Increasing
Slightly volatile
Inventory1.2 B1.4 B242.1 M
Increasing
Slightly volatile
Tax Assets291.7 M293.4 M320.9 M
Decreasing
Slightly volatile
Trade and Non Trade Receivables3.4 B3.2 B624.4 M
Increasing
Slightly volatile
Trade and Non Trade Payables325.8 M302 M69.4 M
Increasing
Slightly volatile
Total Liabilities11.4 B10.5 B2.5 B
Increasing
Slightly volatile
Shareholders Equity15.3 B14.1 B2.4 B
Increasing
Slightly volatile
Accumulated Retained Earnings Deficit10.7 B10 B982.6 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(24.6 M)(24 M)(3.8 M)
Decreasing
Slightly volatile
Current Assets17.3 B16.1 B3.9 B
Increasing
Slightly volatile
Assets Non Current9.3 B8.6 B1.7 B
Increasing
Slightly volatile
Current Liabilities9.8 B9.1 B1.9 B
Increasing
Slightly volatile
Liabilities Non Current1.5 B1.4 B532.7 M
Increasing
Slightly volatile
Tax Liabilities783.8 M788.4 M862.2 M
Decreasing
Slightly volatile
Total Debt760.7 M705 M149.4 M
Increasing
Slightly volatile
Debt Non Current760.7 M705 M149.4 M
Increasing
Slightly volatile
Shareholders Equity USD15.3 B14.1 B2.4 B
Increasing
Slightly volatile
Cash and Equivalents USD7.4 B6.8 B1.4 B
Increasing
Slightly volatile
Total Debt USD760.7 M705 M149.4 M
Increasing
Slightly volatile

Moderna Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues19.9 B18.5 B3.1 B
Increasing
Slightly volatile
Cost of Revenue2.1 B2.6 B372.5 M
Increasing
Slightly volatile
Selling General and Administrative Expense611.8 M567 M156.8 M
Increasing
Slightly volatile
Research and Development Expense2.1 BB676.4 M
Increasing
Slightly volatile
Operating Expenses2.8 B2.6 B833.1 M
Increasing
Slightly volatile
Income Tax Expense1.2 B1.1 B173.9 M
Increasing
Slightly volatile
Consolidated Income13.2 B12.2 B1.7 B
Increasing
Slightly volatile
Net Income13.2 B12.2 B1.7 B
Increasing
Slightly volatile
Preferred Dividends Income Statement Impact19.1 M19.7 M15.6 M
Increasing
Slightly volatile
Net Income Common Stock13.2 B12.2 B1.7 B
Increasing
Slightly volatile
Weighted Average Shares339.6 M403 M155.8 M
Increasing
Slightly volatile
Weighted Average Shares Diluted357 M431 M159.3 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT14.3 B13.3 B1.9 B
Increasing
Slightly volatile
Revenues USD19.9 B18.5 B3.1 B
Increasing
Slightly volatile
Net Income Common Stock USD13.2 B12.2 B1.7 B
Increasing
Slightly volatile
Earning Before Interest and Taxes USD14.3 B13.3 B1.9 B
Increasing
Slightly volatile
Gross Profit17.1 B15.9 B2.7 B
Increasing
Slightly volatile
Operating Income14.3 B13.3 B1.9 B
Increasing
Slightly volatile

Moderna Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals(8.5 B)(8.2 B)(1.7 B)
Decreasing
Slightly volatile
Net Cash Flow from Financing(896 M)(873 M)373.3 M
Decreasing
Stable
Issuance Repayment of Debt Securities (143.7 M)(140 M)(20.6 M)
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares(752.3 M)(733 M)90 M
Increasing
Very volatile
Net Cash Flow from Investing(8.7 B)(8.5 B)(1.8 B)
Decreasing
Slightly volatile
Net Cash Flow from Operations14.7 B13.6 B2.3 B
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents4.6 B4.2 B814.9 M
Increasing
Slightly volatile
Share Based Compensation119.9 M142 M63.4 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion250.3 M232 M58.3 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share32.7130.311.8343
Increasing
Slightly volatile
Earnings per Diluted Share30.5228.291.5109
Increasing
Slightly volatile
Earnings per Basic Share USD32.7130.311.8343
Increasing
Slightly volatile
Return on Average Equity1.511.4020.4821
Decreasing
Very volatile
Return on Average Assets0.710.656(0.085)
Increasing
Slightly volatile
Return on Invested Capital3.513.2510.2607
Increasing
Slightly volatile
Gross Margin0.860.8580.9777
Decreasing
Slightly volatile
Profit Margin0.710.661(2.0989)
Increasing
Stable
EBITDA Margin0.790.732(1.8526)
Increasing
Stable
Return on Sales0.770.719(2.0002)
Increasing
Stable
Asset Turnover1.070.9930.2839
Increasing
Slightly volatile
Enterprise Value over EBITDA7.87.233(13.8556)
Increasing
Very volatile
Enterprise Value over EBIT7.557.0(12.9575)
Increasing
Very volatile
Price to Earnings Ratio9.048.379(5.8665)
Decreasing
Stable
Sales per Share49.4545.8348.8401
Increasing
Slightly volatile
Price to Sales Ratio5.685.54119.3254
Increasing
Stable
Price to Book Value8.497.285.1229
Increasing
Slightly volatile
Debt to Equity Ratio0.80.744(0.6779)
Increasing
Slightly volatile
Current Ratio1.811.7615.4416
Decreasing
Slightly volatile
Free Cash Flow per Share35.7133.0924.9923
Increasing
Slightly volatile
Book Value per Share37.8735.0994.2285
Increasing
Slightly volatile
Tangible Assets Book Value per Share66.0461.21327.3556
Increasing
Slightly volatile

Moderna Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax14.3 B13.3 B1.9 B
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA14.6 B13.5 B1.9 B
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD14.6 B13.5 B1.9 B
Increasing
Slightly volatile
Market Capitalization111.1 B103 B23.6 B
Increasing
Slightly volatile
Enterprise Value105.5 B97.8 B22.5 B
Increasing
Slightly volatile
Invested Capital10.1 B9.4 B2.4 B
Increasing
Slightly volatile
Average Equity9.4 B8.7 B1.4 B
Increasing
Slightly volatile
Average Assets20.1 B18.6 B4.3 B
Increasing
Slightly volatile
Invested Capital Average4.4 B4.1 B1.6 B
Increasing
Slightly volatile
Tangible Asset Value26.6 B24.7 B5.6 B
Increasing
Slightly volatile
Free Cash Flow14.4 B13.3 B2.2 B
Increasing
Slightly volatile
Working Capital7.5 B6.9 BB
Increasing
Slightly volatile

Moderna Fundamental Market Drivers

Short Percent Of Float5.20%
Forward Price Earnings15.72
Shares Short Prior Month16.21M
Average Daily Volume Last 10 Day6.79M
Average Daily Volume In Three Month7.17M
Date Short Interest29th of April 2022
Fifty Day Average154.28
Two Hundred Day Average251.87

Moderna Upcoming Events

Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Moderna Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moderna income statement, its balance sheet, and the statement of cash flows. Moderna investors use historical funamental indicators, such as Moderna's revenue or net income, to determine how well the company is positioned to perform in the future. Although Moderna investors may use each financial statement separately, they are all related. The changes in Moderna's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moderna's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moderna Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue6.9 B7.4 B
Cost of Revenue2.6 B2.1 B
Revenues18.5 B19.9 B
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2700 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Search Now

   

Equity Search

Search for actively traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Moderna Correlation against competitors. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.